SCHLIEREN (ZURICH), Switzerland, July 15, 2021 (GLOBE NEWSWIRE) -- Kuros Biosciences AG ("Kuros" or the "Company"), a leader in next generation bone graft technologies, announced today that it has entered into a royalty purchase agreement with XOMA Corporation (NASDAQ: XOMA) under which XOMA has purchased a proportion of the potential future pre-commercial milestone payments and all the potential royalties due under the existing license agreement between Kuros and Checkmate Pharmaceuticals related to one of Kuros's assets outside of the bone graft field. Kuros will receive an initial payment of $7 million from XOMA. In addition, Kuros retains the potential to receive up to $24 million in pre-commercial milestones from Checkmate, and is eligible to receive up to $142.5 million in sales milestones from Xoma.